4,839 results
Search Results
2. Heritable and spatial immunogenic traits co-predict the efficacy of immunotherapy in kidney cancer.
- Subjects
- Humans, Kidney Neoplasms immunology, Kidney Neoplasms therapy, Kidney Neoplasms genetics, Immunotherapy
- Published
- 2024
- Full Text
- View/download PDF
3. Studying paired patient tissue and blood enables insights into immunotherapy toxicity.
- Subjects
- Humans, Neoplasms immunology, Neoplasms therapy, Neoplasms drug therapy, Immunotherapy adverse effects
- Published
- 2024
- Full Text
- View/download PDF
4. Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper
- Author
-
Hong Qin, Changqiao You, Feng Yan, Kefang Tan, Changgen Xu, Rui Zhao, Marlene Davis Ekpo, and Songwen Tan
- Subjects
natural killer (NK) cells ,immunosenescence ,immunotherapy ,cancer ,chemotherapy ,biotherapeutics ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2022
- Full Text
- View/download PDF
5. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.
- Author
-
Rees MJ and Kumar S
- Subjects
- Humans, Risk Factors, Prognosis, Multiple Myeloma genetics, Multiple Myeloma therapy, Multiple Myeloma diagnosis, Immunotherapy
- Abstract
Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and treatment response. Despite therapeutic advances, some patients continue to relapse early (ER, <18-months) and rapidly cycle through therapies. Myriad prognostic factors have been identified and incorporated into risk stratification models; however, these produce discordant, often three-tiered outputs that fail to identify many patients destined for ER. Treatment strategies are increasingly focused on disease biology and trials enriched for high-risk (HR)MM, but consensus on the minimum required testing and a succinct, specific, and clinically meaningful definition for HRMM remains elusive. We review the risk-factors, definitions, and future directions for HRMM., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
6. Allergen Content of Therapeutic Preparations for Allergen-Specific Immunotherapy of European Paper Wasp Venom Allergy.
- Author
-
Grosch, Johannes, Lesur, Antoine, Kler, Stéphanie, Bernardin, François, Dittmar, Gunnar, Francescato, Elisabetta, Hewings, Simon J., Jakwerth, Constanze A., Zissler, Ulrich M., Heath, Matthew D., Ollert, Markus, Kramer, Matthias F., Hilger, Christiane, Bilò, Maria Beatrice, Schmidt-Weber, Carsten B., and Blank, Simon
- Subjects
- *
ALLERGENS , *SNAKE venom , *VENOM , *ALLERGENIC extracts , *WASPS , *IMMUNOTHERAPY , *LIQUID chromatography-mass spectrometry , *VENOM hypersensitivity - Abstract
Allergy to Polistes dominula (European paper wasp) venom is of particular relevance in Southern Europe, potentially becoming a threat in other regions in the near future, and can be effectively cured by venom immunotherapy (VIT). As allergen content in extracts may vary and have an impact on diagnostic and therapeutic approaches, the aim was to compare five therapeutic preparations for VIT of P. dominula venom allergy available in Spain. Products from five different suppliers were analyzed by SDS-PAGE and LC-MS/MS and compared with a reference venom sample. Three products with P. dominula venom and one product with a venom mixture of American Polistes species showed a comparable band pattern in SDS-PAGE as the reference sample and the bands of the major allergens phospholipase A1 and antigen 5 were assignable. The other product, which consists of a mixture of American Polistes species, exhibited the typical band pattern in one, but not in another sample from a second batch. All annotated P. dominula allergens were detected at comparable levels in LC-MS/MS analysis of products containing P. dominula venom. Due to a lack of genomic information on the American Polistes species, the remaining products were not analyzed by this method. The major Polistes allergens were present in comparable amounts in the majority, but not in all investigated samples of venom preparations for VIT of P. dominula venom allergy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Diagnostic therapeutic care pathway for pediatric food allergies and intolerances in Italy: a joint position paper by the Italian Society for Pediatric Gastroenterology Hepatology and Nutrition (SIGENP) and the Italian Society for Pediatric Allergy and Immunology (SIAIP)
- Author
-
Berni Canani, Roberto, Caffarelli, Carlo, Calvani, Mauro, Martelli, Alberto, Carucci, Laura, Cozzolino, Tommaso, Alvisi, Patrizia, Agostoni, Carlo, Lionetti, Paolo, and Marseglia, Gian Luigi
- Subjects
- *
TREATMENT of food intolerance , *DIAGNOSIS of food allergies , *SKIN tests , *FOOD intolerance , *PEDIATRICS , *HEALTH care teams , *PROFESSIONAL associations , *FOOD allergy , *IMMUNOTHERAPY , *SYMPTOMS , *CHILDREN - Abstract
Epidemiologic data suggest an increased prevalence of pediatric food allergies and intolerances (FAIs) during the last decades. This changing scenario has led to an increase in the overall healthcare costs, due to a growing demand for diagnostic and treatment services. There is the need to establish Evidence-based practices for diagnostic and therapeutic intervention that could be adopted in the context of public health policies for FAIs are needed. This joint position paper has been prepared by a group of experts in pediatric gastroenterology, allergy and nutrition from the Italian Society for Pediatric Gastroenterology Hepatology and Nutrition (SIGENP) and the Italian Society for Pediatric Allergy and Immunology (SIAIP). The paper is focused on the Diagnostic Therapeutic Care Pathway (DTCP) for pediatric FAIs in Italy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer
- Author
-
Aristei, C., Kaidar-Person, O., Boersma, L., Leonardi, M. C., Offersen, B., Franco, P., Arenas, M., Bourgier, C., Pfeffer, R., Kouloulias, V., Bölükbaşı, Y., Meattini, I., Coles, C., Luis, A. Montero, Masiello, V., Palumbo, I., Morganti, A. G., Perrucci, E., Tombolini, V., Krengli, M., Marazzi, F., Trigo, L., Borghesi, S., Ciabattoni, A., Ratoša, I., Valentini, V., and Poortmans, P.
- Subjects
Radiation therapy ,Breast cancer ,Oncology ,Re-irradiation in relapsed patients ,Immunotherapy ,Hematology ,Combined modality treatment - Abstract
The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals.
- Published
- 2023
9. Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer.
- Author
-
Hu Q, Wang S, Ma L, Sun Z, Liu Z, Deng S, and Zhou J
- Subjects
- Humans, SARS-CoV-2, Radiation Pneumonitis diagnostic imaging, Radiation Pneumonitis etiology, Lung Neoplasms drug therapy, Lung Neoplasms diagnostic imaging, Lung Neoplasms immunology, Lung Neoplasms pathology, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Pneumonia diagnostic imaging, Pneumonia chemically induced, Pneumonia etiology, Immunotherapy adverse effects, Immunotherapy methods, COVID-19 immunology, Tomography, X-Ray Computed methods
- Abstract
Immune checkpoint inhibitors (ICIs) therapy have revolutionized advanced lung cancer care. Interestingly, the host responses for patients received ICIs therapy are distinguishing from those with cytotoxic drugs, showing potential initial transient worsening of disease burden, pseudoprogression and delayed time to treatment response. Thus, a new imaging criterion to evaluate the response for immunotherapy should be developed. ICIs treatment is associated with unique adverse events, including potential life-threatening immune checkpoint inhibitor-related pneumonitis (ICI-pneumonitis) if treated patients are not managed promptly. Currently, the diagnosis and clinical management of ICI-pneumonitis remain challenging. As the clinical manifestation is often nonspecific, computed tomography (CT) scan and X-ray films play important roles in diagnosis and triage. This article reviews the complications of immunotherapy in lung cancer and illustrates various radiologic patterns of ICI-pneumonitis. Additionally, it is tried to differentiate ICI-pneumonitis from other pulmonary pathologies common to lung cancer such as radiation pneumonitis, bacterial pneumonia and coronavirus disease of 2019 (COVID-19) infection in recent months. Maybe it is challenging to distinguish radiologically but clinical presentation may help., (© 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. Clinical outcome and component-specific antibody levels in egg allergic children after lightened oral immunotherapy.
- Author
-
Koffert A, Liippo J, Löyttyniemi E, and Savolainen J
- Subjects
- Child, Humans, Powders, Immunoglobulin A, Immunoglobulin E, Immunoglobulin G, Immunotherapy, Eggs
- Abstract
Objective: To evaluate the clinical outcome of lightened version of egg oral immunotherapy (OIT) and to analyze egg allergen component-specific antibody levels during short up-dosing with egg white powder and maintenance by egg in daily diet., Patients and Methods: Eighteen egg-allergic children received egg powder with short up--dosing and they maintained tolerance using egg in daily diet. Seventeen egg-allergic children served as a control group. Component-resolved analysis of serum immunoglobulin E (IgE), IgA1, IgA2, and IgG4 levels were determined at inclusion, after up-dosing and after 1 year of immunotherapy. Skin-prick tests were performed at inclusion and after 1 year of therapy., Results: All 18 patients in the egg OIT group were successfully desensitized. Desensitization was achieved on average in 4.5 months. In the control group, only two children tolerated egg in oral food challenge after 1 year. Of the measured immune markers, smaller wheal diameters in skin-prick testing, reduction in component-specific IgE levels, and increase in component-specific IgA1, IgA2, and IgG4 levels were associated with desensitization., Conclusion: A lightened egg OIT is effective and safe in children with egg allergy. Increase in all egg component-specific IgA1, IgA2 and IgG4 levels and decrease in all egg component--specific IgE levels were observed after 12 months of OIT.
- Published
- 2024
- Full Text
- View/download PDF
11. Candidacy for extracorporeal life support (ECLS) in children after hematopoietic cell transplantation (HCT): a position paper from the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network’s Hematopoietic Cell Transplant and Cancer Immunotherapy (CI) subgroup
- Author
-
Zinter, Matt S., McArthur, Jennifer, Duncan, Christine, Adams, Roberta, Kreml, Erin, Dalton, Heidi, Abdel-Azim, Hisham, Rowan, Courtney M., Gertz, Shira J., Mahadeo, Kris M., Randolph, Adrienne G., Rajapreyar, Prakadeshwari, Steiner, Marie E., and Lehmann, Leslie
- Subjects
Extracorporeal Membrane Oxygenation ,Critical Illness ,Neoplasms ,Sepsis ,Acute Lung Injury ,Hematopoietic Stem Cell Transplantation ,Humans ,Immunotherapy ,Child ,Article - Abstract
The last decade has seen improved outcomes for children requiring extracorporeal life support as well as for children undergoing hematopoietic cell transplantation. Thus, given the historically poor survival of hematopoietic cell transplantation patients using extracorporeal life support, the Pediatric Acute Lung Injury and Sepsis Investigators' hematopoietic cell transplantation and cancer immunotherapy subgroup aimed to characterize the utility of extracorporeal life support in facilitating recovery from critical cardiorespiratory illnesses in pediatric hematopoietic cell transplantation patients.All available published data were identified using a set of PubMed search terms for pediatric extracorporeal life support and hematopoietic cell transplantation.All articles that provided original reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support were included. Sixty-four manuscripts met search criteria. Twenty-four were included as primary reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support (11 were single case reports, four single institution case series, two multi-institution case series, and seven registry reports from Extracorporeal Life Support Organization, Pediatric Heath Information System, and Virtual Pediatric Systems).All 24 articles were reviewed by first and last authors and a spread sheet was constructed including sample size, potential biases, and conclusions.Discussions regarding incorporation of available evidence into our clinical practice were held at biannual meetings, as well as through email and virtual meetings. An expert consensus was determined through these discussions and confirmed through a modified Delphi process.Extracorporeal life support in hematopoietic cell transplantation patients is being used with increasing frequency and potentially improving survival. The Pediatric Acute Lung Injury and Sepsis Investigators hematopoietic cell transplantation-cancer immunotherapy subgroup has developed a framework to guide physicians in decision-making surrounding extracorporeal life support candidacy in pediatric hematopoietic cell transplantation patients. In addition to standard extracorporeal life support considerations, candidacy in the hematopoietic cell transplantation population should consider the following six factors in order of consensus agreement: 1) patient comorbidities; 2) underlying disease necessitating hematopoietic cell transplantation; 3) hematopoietic cell transplantation toxicities, 4) family and patient desires for goals of care; 5) hematopoietic cell transplantation preparatory regimen; and 6) graft characteristics. Although risk assessment may be individualized, data are currently insufficient to clearly delineate ideal candidacy. Therefore, we urge the onco-critical care community to collaborate and capture data to provide better evidence to guide physicians' decision-making in the future.
- Published
- 2022
12. Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
- Author
-
Tempo, Jake, Bolton, Damien, and O'Callaghan, Michael
- Subjects
TRANSITIONAL cell carcinoma ,BCG immunotherapy ,UROLOGY ,IMMUNOTHERAPY ,ONCOLOGY - Abstract
The South West Oncology Group's 2000 randomised-control trial investigated the addition of maintenance intravesical bacillus Calmette-Guerin (BCG) to non-muscle invasive urothelial carcinoma (NMIUC) treatment. The results were published when the efficacy of BCG immunotherapy maintenance was unclear. Randomisation produced two arms, each containing 192 patients assessed to be at high risk of recurrence following induction BCG therapy for NMIUC. The treatment arm went on to receive three successive weekly intravesical and percutaneous BCG administrations at three months, six months and then six monthly for three years from the start of induction therapy. Recurrence free-survival (RFS), was higher in the maintenance arm with 41% (95%CI 35–49) RFS at five years in the control arm and 60% RFS (53–67 95% CI) in the maintenance arm (p < 0.0001). Only 16% of patients in the treatment arm received all of the scheduled maintenance courses of BCG. The study's seminal results correlate with contemporary systematic review and have guided international guidelines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. The complementarity of DDR, nucleic acids and anti-tumour immunity.
- Author
-
Kornepati AVR, Rogers CM, Sung P, and Curiel TJ
- Subjects
- Humans, Antigens, Neoplasm immunology, Antigens, Neoplasm metabolism, DNA Repair, DNA Replication, Mutation, Biomarkers, Tumor, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, DNA Damage, Immunotherapy methods, Immunotherapy trends, Neoplasms genetics, Neoplasms immunology, Neoplasms metabolism, Neoplasms therapy, Nucleic Acids metabolism, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use
- Abstract
Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore, only a minority of patients with cancer benefit from ICB, and there is a lack of fully informative treatment response biomarkers. Selectively exploiting defects in DNA damage repair is also a standard treatment for cancer, spurred by enhanced understanding of the DNA damage response (DDR). DDR and ICB are closely linked-faulty DDR produces immunogenic cancer neoantigens that can increase the efficacy of ICB therapy, and tumour mutational burden is a good but imperfect biomarker for the response to ICB. DDR studies in ICB efficacy initially focused on contributions to neoantigen burden. However, a growing body of evidence suggests that ICB efficacy is complicated by the immunogenic effects of nucleic acids generated from exogenous DNA damage or endogenous processes such as DNA replication. Chemotherapy, radiation, or selective DDR inhibitors (such as PARP inhibitors) can generate aberrant nucleic acids to induce tumour immunogenicity independently of neoantigens. Independent of their functions in immunity, targets of immunotherapy such as cyclic GMP-AMP synthase (cGAS) or PD-L1 can crosstalk with DDR or the DNA repair machinery to influence the response to DNA-damaging agents. Here we review the rapidly evolving, multifaceted interfaces between DDR, nucleic acid immunogenicity and immunotherapy efficacy, focusing on ICB. Understanding these interrelated processes could explain ICB treatment failures and reveal novel exploitable therapeutic vulnerabilities in cancers. We conclude by addressing major unanswered questions and new research directions., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
14. Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis.
- Author
-
Yanhao Liu, Xu Cheng, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen, and Xiaotao Zhang
- Abstract
Background: Immunotherapy for lung cancer has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer immunotherapy. Method: On 1 July, 2022, the authors identified 2,941 papers on lung cancer immunotherapy by the Web of Science and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top papers) as well as major journals on lung cancer immunotherapy. After that, recent research hotspots were analyzed based on the latest publications in major journals. Results: These 2,941 papers were cited a total of 122,467 times. “Nivolumab vs. docetaxel in advanced non–squamous non–small–cell lung cancer” published in 2015 by Borghaei H et al. was the most cited paper (5,854 citations). Among the journals, New England Journal of Medicine was most influential. Corresponding authors represented China took part in most articles (904) and papers with corresponding authors from the USA were most cited (139.46 citations per paper). Since 2015, anti–PD–(L)1 has become the hottest research area. Conclusions: This bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on thousands of publications, and further suggests future research directions. Moreover, the results can benefit researchers to select journals and find potential collaborators. This study can help researchers get a comprehensive impression of the research landscape, historical development, and recent hotspots in lung cancer immunotherapy and provide inspiration for further research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis.
- Author
-
Yanhao Liu, Shu Jiang, Yaru Lin, Haiming Yu, Lan Yu, and Xiaotao Zhang
- Subjects
BIBLIOMETRICS ,CANCER radiotherapy ,LUNG cancer ,NON-small-cell lung carcinoma ,STEREOTACTIC radiotherapy - Abstract
Background: radiotherapy is one of the major treatments for lung cancer and has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer radiotherapy. Method: On August 31, 2022, the authors identified 9868 articles on lung cancer radiotherapy by the Web of Science (Science Citation Indexing Expanded database) and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top-papers) as well as top-journals on lung cancer radiotherapy. After that, the authors analyzed the recent research hotspots based on the latest publications in top-journals. Results: These 9868 papers were cited a total of 268,068 times. "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer" published in 2017 by Antonia et al. was the most cited article (2110 citations). Among the journals, New England Journal of Medicine was most influential. Moreover, J. Clin. Oncol. and Int. J. Radiat. Oncol. Biol. Phys. was both influential and productive. Corresponding authors represented the USA (2610 articles) and China mainland (2060 articles) took part in most publications and articles with corresponding authors from Netherlands were most cited (46.12 citations per paper). Chemoradiotherapy was the hottest research area, and stereotactic body radiotherapy has become a research hotspot since 2006. Radiotherapy plus immunotherapy has been highly focused since 2019. Conclusions: This bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on 9868 relevant articles, and further suggests future research directions. The researchers can benefit in selecting journals and in finding potential collaborators. This study can help researchers gain a comprehensive picture of the research landscape, historical development, and recent hotspots in lung cancer radiotherapy and can provide inspiration for future research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Title of presented paper: Chemobrain after anticancer treatment - when the necessary treatment has unpleasant consequences.
- Author
-
Monika, Błądek, Karolina, Drygała, and Gabriela, Barszcz
- Subjects
ANTINEOPLASTIC agents ,CANCER treatment ,COGNITION ,COGNITION disorders ,IMMUNOTHERAPY - Abstract
Introduction and aim. Over the last few decades, there has been tremendous progress in the treatment of cancer. Unfortunately, anti-cancer therapies, although necessary and increasingly effective, still carry many side effects. One of these effects is the chemobrain -- cognitive disorders resulting from strong chemotherapy. The aim of this paper is to review available knowledge of chemobrain. Material and methods. The paper reviews articles available in the PubMed medical database, searched with the phrases "chemobrain", "chemobrain cancer" from the years 2015-2023 which are reviews, systematic reviews or meta-analyses. 41 results were obtained, of which 13 articles were used for the final analysis after the selection of papers strictly related to the issue of chemobrain. Analysis of literature. The occurrence of chemobrain is associated with impaired cognitive abilities, problems with concentration, and memory loss. It may occur only during treatment or persist even after its completion. According to the data, chemobrain occurs much more often as a complication of traditional chemotherapy than in the case of immunotherapy. The mechanism of chemobrain formation is not known. A combination of oxygen radical production and cytokine dysregulation is suspected as an inducer of this complication. Chemobrain treatment strategies remain under development. At the moment, non-pharmacological methods are used in the treatment, such as regular physical exercise, mental exercise, or a diet including omega-3 fatty acids. Pharmacological treatment is still under development and research. Conclusion. Chemobrain is a medical complication that can have a serious psychological impact on patients undergoing anti-cancer therapy, so further research is needed to better understand the mechanism of this phenomenon, which will allow the development of new treatments and possible ways to prevent the occurrence of chemobrain. [ABSTRACT FROM AUTHOR]
- Published
- 2023
17. Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021)
- Author
-
Shanshan Yang, Suya Zhao, Yixiang Ye, Liqun Jia, and Yanni Lou
- Subjects
immunotherapy ,gut microbiota ,cancer ,research trends ,highly cited papers ,bibliometrics ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundThere is a crosstalk between gut microbiota (GM) and cancer immunotherapy (CI). The purpose of this study is to use bibliometric analysis to identify the highly cited papers relating to GM/CI and explore the research status and development trends of the GM/CI research.MethodsA literature search regarding GM/CI publications from 2012 to 2021 was undertaken on July 4, 2022. The article titles, journals, authors, institutions, countries, total citations, keywords, and other information were extracted from the Science Citation Index Expanded (SCIE) of Web of Science Core Collection (WoSCC). The Bibliometrix of R package and VOSviewer were used for bibliometric analysis.ResultsA total of 665 papers were extracted. The number of papers has increased rapidly over the past decade, especially after 2018. The United States and China had the most publications and made great contributions to this field. Th5e Univ Texas MD Anderson Canc Ctr and Univ Paris Saclay were absolutely in the leading position in GM/CI. The most influential authors were Zitvogel L and Routy B. Frontiers in Immunology had the most publications and Science had the most total citations. Historical direct citation analysis explained the historical evolution in GM/CI. Highly cited papers and high-frequency keywords illustrated the current status and trends of GM/CI. Four clusters were identified and the important topics included the role of GM and antibiotics in CI, the methods of targeting GM to improve CI outcomes, the mechanism by which GM affects CI and the application of ICIs in melanoma. “Tumor microbiome”, “proton pump inhibitors” and “prognosis” may be the new focus of attention in the next few years.ConclusionThis study filtered global publications on GM/CI correlation and analyzed their bibliometric characteristics, identified the most cited papers in GM/CI, and gained insight into the status, hotspots and trends of global GM/CI research, which may inform researchers and practitioners of future directions.
- Published
- 2022
- Full Text
- View/download PDF
18. Top 100 Most Cited Publications on CTLA-4 Molecule in Cancer Research: A Bibliometric Analysis.
- Author
-
El Idrissi, Hossam Hilal and Balar, Ibtissam
- Subjects
TUMOR treatment ,PROTEINS ,ONLINE information services ,SERIAL publications ,BIBLIOMETRICS ,CITATION analysis ,DESCRIPTIVE statistics ,T cells ,MEDLINE ,MEDICAL research ,IMMUNOTHERAPY - Abstract
The aim of this research is to use bibliometric analysis to investigate the status and patterns of the 100 most frequently cited publications regarding the cytotoxic T-lymphocyte-associated protein (CTLA-4) research for cancer. The articles published on the topic were retrieved from the core collection database of Web of Science and PubMed using the Medical Subject Heading (MeSH) of "CTLA-4" from 1986 to December 6, 2020. The selected articles were examined and the bibliometric data compiled based on the number of citations, the author's name, journal, publication year, institution, country, and co-occurrence keywords. 4,874 eligible papers were returned from the Web of Science Core Collection Database and PubMed. The citation frequency ranged from 2372 to 205, with a median of 460, and the top cited paper had 2372 citations. The journals with the most papers were Cell (n = 8, 3541 citations, Impact Factor (IF) = 41.577) and Journal of Experimental Medicine (n = 7, 2716 citations, IF = 10.790). Most of the published papers were from the United States of America (USA) (41.8%). A total of 485 institutes and 29 countries were involved in these 100 articles. There were 1192 authors and the author with the highest number of papers was the Nobel Prize winner, Professor James P. Allison (17 papers; 8700 citations). CTLA-4 blockade was the most frequent keyword (42.1%), followed by metastatic melanoma (4.26%). This work presents an important bibliographic source and can be saved as a reference for future medical health research on the function of CTLA-4 in cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Title of presented paper: Mucosal IgE production in local allergic rhinitis, a potential diagnostic criterion, and an implementation in allergen immunotherapy.
- Author
-
Mortada, Mohamad Mahdi
- Subjects
ALLERGIC rhinitis ,IMMUNOTHERAPY ,RHINORRHEA ,IMMUNOGLOBULIN E - Abstract
Introduction and aim. Local allergic rhinitis (LAR) patients are diagnosed based on the presence of clinical symptoms such as rhinorrhea, sneezing, and nasal itching with negative skin prick testing and negative serum-specific immunoglobulin E (sIgE) assessment for the specific allergen. Our paper aims to provide insight into the pathogenesis of LAR, the local production of IgE in the nasal mucosa, and challenges associated with the investigation of this phenomenon. The current state of knowledge and future research perspectives on the management of LAR patients are presented. Material and methods. This review included literature searched using Medline, Embase, and PubMed. A total of 53 articles were identified initially and after applying the exclusion criteria 38 articles (32 original and 6 reviews) were selected for the analysis of literature. Analysis of literature. Based on the assessed studies, not only patients with allergic rhinitis (AR) show the presence of nasal IgE for the specific allergen (Mites, pollen, and molds), but also those who are classified in the non-allergic rhinitis (NAR) and LAR groups. The results support the hypothesis stating that NAR/LAR patients may have local production of IgE at the level of nasal mucosa following local inflammation due to exposure to specific allergens. Conclusion. The possibility to assess the local synthesis of sIgE and other mediators can help in adding allergen immunotherapy (AIT) to the management protocol of LAR patients and may provide new insights into phenotypical and endotypical classification of AR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
20. Using DNA sequencing data to quantify T cell fraction and therapy response.
- Author
-
Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA, Jamal-Hanjani M, Swanton C, and McGranahan N
- Subjects
- Adenocarcinoma of Lung diagnosis, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung immunology, Adenocarcinoma of Lung therapy, Aspartic Acid Endopeptidases genetics, Cohort Studies, Exome genetics, Female, Humans, Lymphocytes, Tumor-Infiltrating immunology, Male, Mutation, Neoplasms diagnosis, Neoplasms genetics, Prognosis, Receptors, Antigen, T-Cell, alpha-beta genetics, Exome Sequencing economics, Immunotherapy, Neoplasms immunology, Neoplasms therapy, T-Lymphocytes cytology, T-Lymphocytes metabolism
- Abstract
The immune microenvironment influences tumour evolution and can be both prognostic and predict response to immunotherapy
1,2 . However, measurements of tumour infiltrating lymphocytes (TILs) are limited by a shortage of appropriate data. Whole-exome sequencing (WES) of DNA is frequently performed to calculate tumour mutational burden and identify actionable mutations. Here we develop T cell exome TREC tool (T cell ExTRECT), a method for estimation of T cell fraction from WES samples using a signal from T cell receptor excision circle (TREC) loss during V(D)J recombination of the T cell receptor-α gene (TCRA (also known as TRA)). TCRA T cell fraction correlates with orthogonal TIL estimates and is agnostic to sample type. Blood TCRA T cell fraction is higher in females than in males and correlates with both tumour immune infiltrate and presence of bacterial sequencing reads. Tumour TCRA T cell fraction is prognostic in lung adenocarcinoma. Using a meta-analysis of tumours treated with immunotherapy, we show that tumour TCRA T cell fraction predicts immunotherapy response, providing value beyond measuring tumour mutational burden. Applying T cell ExTRECT to a multi-sample pan-cancer cohort reveals a high diversity of the degree of immune infiltration within tumours. Subclonal loss of 12q24.31-32, encompassing SPPL3, is associated with reduced TCRA T cell fraction. T cell ExTRECT provides a cost-effective technique to characterize immune infiltrate alongside somatic changes., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2021
- Full Text
- View/download PDF
21. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
- Author
-
Liu, Yanhao, Xu, Yan, Cheng, Xi, Lin, Yaru, Jiang, Shu, Yu, Haiming, Zhang, Zhen, Lu, Linlin, and Zhang, Xiaotao
- Subjects
NON-small-cell lung carcinoma ,BIBLIOMETRICS ,IMMUNOTHERAPY ,CELL death - Abstract
In this study, a bibliometric analysis was carried out to identify the most influential clinical studies and research trends on anti-programmed cell death 1/programmed cell death 1 ligand 1 (anti-PD1/PDL1) immunotherapy. On January 1, 2022, we used Web of Science to identify the 100 most frequently cited papers on clinical studies investigating anti-PD1/PDL1 immunotherapy, and extracted the following data: publication year, source title, country/region, institution, and the total number of citations. The research design and area were classified independently by the authors. Subsequently, we carried out a bibliometric analysis to determine the trends and identify the major journals on anti-PD1/PDL1 immunotherapy. The authors analyzed the current research hotspots based on papers published in major journals from 2020 to 2021. These 100 papers were cited a total of 138,840 times, and the median number of citations was 899.5 (range: 341–7,983). "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer" by Topalian et al. had the highest number of citations (7,983 times). New England Journal of Medicine had the highest number of top-cited papers (40 papers), average citations per paper (1,558.3 citations), and rate of top-cited papers (65.6%). Authors from the USA contributed most of the papers (76 papers). Lung cancer (30 papers, 46,422 citations) and melanoma (20 papers, 30,881 citations) were the most cited research areas. In summary, anti-PD1/PDL1 has become standard treatment for various cancer, while adjuvant anti-PD1/PDL1 therapy is currently a research hotspot. New England Journal of Medicine was identified as the most influential journal in this area. Non-small cell lung cancer and melanoma are the most well-studied cancers, while nivolumab and pembrolizumab are the most commonly investigated anti-PD1/PDL1 antibodies. Further studies are warranted to identify effective predictive biomarkers or models, clarify the molecular mechanism of combined therapy, and establish optimal therapeutic strategies. This study may assist researchers in obtaining a comprehensive impression of the landscape and current trends in anti-PD1/PDL1 immunotherapy and gain inspiration to conduct further studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy.
- Author
-
Liu, Yanhao, Li, Jinying, Cheng, Xu, and Zhang, Xiaotao
- Subjects
STEREOTACTIC radiotherapy ,NON-small-cell lung carcinoma ,BIBLIOMETRICS ,LUNG cancer - Abstract
Objective: This study aims to analyze the 100 most cited papers and research trends on stereotactic body radiotherapy (SBRT). Methods: We used Web of Science to identify the 100 most frequently cited papers on SBRT on September 29, 2021 and extracted the following data: publication year, source title, country/region, organization, total citations, and average number of citations per year. The research type and research domain were classified independently by the authors. Then we carried out a bibliometric analysis to determine the trends in research on SBRT. Results: These 100 papers were cited a total of 26,540 times, and the median number of citations was 190 (range, 138-1688). "Stereotactic body radiation therapy for inoperable early stage lung cancer" by Timmerman et al. had the highest number of total citations (1688 times). International Journal of Radiation Oncology, Biology, Physics published the largest number of papers (37 papers), followed by Journal of Clinical Oncology (13 papers). The USA contributed the most papers (67 papers), followed by Canada (18 papers). Primary lung cancer (33 papers, 10,683 citations) and oligometastases (30 papers, 7,147 citations) were the most cited research areas. Conclusions: To the best of our knowledge, this is the first bibliometric analysis of the most frequently cited papers on SBRT. Our results provide insight into the historical development of SBRT and important advances in its application to cancer treatment. Early-stage non–small-cell lung cancer and oligometastases were the most cited research areas in the top 100 publications on SBRT, and SBRT combined with immunotherapy was a hot topic in the past few years. This study is helpful for researchers to identify the most influential papers and current research hotspots on SBRT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper.
- Author
-
Raoul, Jean-Luc, Edeline, Julien, Simmet, Victor, Moreau-Bachelard, Camille, Gilabert, Marine, and Frénel, Jean-Sébastien
- Subjects
- *
DRUG efficacy , *IMMUNE checkpoint inhibitors , *GUT microbiome , *ORAL drug administration , *ANTINEOPLASTIC agents , *PROTON pump inhibitors , *PROTEIN-tyrosine kinase inhibitors , *ANTIMETABOLITES , *DRUG interactions , *INTESTINAL absorption , *HEARTBURN , *TUMORS , *IMMUNOTHERAPY - Abstract
Simple Summary: Proton pump inhibitors are frequently used in cancer patients to alleviate some symptoms, epigastric pain or heartburn. However, acid suppression decreases the absorption of some oral-targeted anticancer treatments (tyrosine kinase inhibitors, CDK4/6 inhibitors) and induces changes in the gut microbiome. Recent data are showing that these interactions have important clinical impacts and medical oncologists and patients must be aware of these possible interactions. Multikinase inhibitors (MKIs), and particularly tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (CPIs), are currently some of the major breakthroughs in cancer treatment. Proton pump inhibitors (PPIs) revolutionised the treatment of acid-related diseases, but are frequently overused for epigastric pain or heartburn. However, long-term acid suppression from using PPIs may lead to safety concerns, and could have a greater impact in cancer patients undergoing therapy, like bone fractures, renal toxicities, enteric infections, and micronutrient deficiencies (iron and magnesium). Moreover, acid suppression may also affect the pharmacokinetics of drugs (at least during acid suppression) and decrease the absorption of many molecularly-targeted anticancer therapies, which are mostly weak bases with pH-dependent absorption. This type of drug-drug interaction may have detrimental effects on efficacy, with major clinical impacts described for some orally administrated targeted therapies (erlotinib, gefitinib, pazopanib, palbociclib), and conflicting results with many others, including capecitabine. Furthermore, the long-term use of PPIs results in severe alterations to the gut microbiome and recent retrospective analyses have shown that the benefit of using CPIs was suppressed in patients treated with PPIs. These very expensive drugs are of great importance because of their efficacy. As the use of PPIs is not essential, we must apply the precautionary principle. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Title of presented paper: The role of monoclonal antibodies in melanoma immunotherapy.
- Author
-
Roztoczyńska, Aleksandra and Jeńć, Aleksandra
- Subjects
MONOCLONAL antibodies ,MELANOMA immunotherapy ,SYSTEMIC family therapy ,CANCER cells - Abstract
Introduction and aim. Melanoma is a malignant neoplasm of melanocytic origin, the development of which largely depends on the influence of UV radiation. Its development is preceded by the appearance of a melanocytic (dysplastic) nevus. Treatment of patients with metastases to distant organs remains the greatest challenge, as the results of treatment in patients with stage IV melanoma are still unsatisfactory. The progress in systemic therapy of generalized melanoma is based on two mechanisms: molecularly targeted treatment and non-specific melanoma immunotherapy, which is characterized by a unique action - instead of inducing the destruction of tumor cells, it strengthens or stimulates the anti-tumor response of the patient's immune system. Immunotherapy uses ipilimumab and Nivolumab that uses the natural ability of the immune system to eliminate primary cancer cells. It inhibits the binding of the cytotoxic T-4 antigen to its ligands, thereby enhancing T-cell response and tumor resistance. The aim of the study was a presentation of the role of monoclonal antibodies in the treatment of melanoma. Material and methods. During the preparation of the presentation 4 databases (PubMed, Google Scholar, Sciencedirect, Medscape) were searched for studies science publications from march 2019 to March 2023 in English. The search terms were: „ipilimumab in melanoma" „ monoclonal antibodies in melanoma treatment" "nivolumab in melanoma" in the title or abstract or as keywords. A total of 660 references, excluding duplicates, were identified. Analysis of literature. Studies show that nivolumab in combination with ipilimumab reduced the risk of death by 45%, compared to ipilimumab monotherapy. The two-year overall survival rate was 64% for nivolumab in combination with ipilimumab, 59% for nivolumab monotherapy, and 45% for ipilimumab monotherapy. Conclusion. Monoclonal antibodies against various immune checkpoints have revolutionized the treatment of metastatic and inoperable melanoma. The combination of two monoclonal antibodies, e.g. ipilimumab with nivolumab, is much more effective than the use of these antibodies in monotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
25. Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO).
- Author
-
Restaino, Stefano, Pellecchia, Giulia, Arcieri, Martina, Bogani, Giorgio, Taliento, Cristina, Greco, Pantaleo, Driul, Lorenza, Chiantera, Vito, Ercoli, Alfredo, Fanfani, Francesco, Fagotti, Anna, Ciavattini, Andrea, Scambia, Giovanni, and Vizzielli, Giuseppe
- Subjects
MEDICAL protocols ,HYSTERECTOMY ,CERVIX uteri tumors ,INTERPROFESSIONAL relations ,DISEASE management ,GYNECOLOGIC care ,CANCER patient medical care ,SENTINEL lymph nodes ,ABDOMINAL surgery ,IMMUNOTHERAPY ,INTERNATIONAL agencies ,MEDICAL societies ,MINIMALLY invasive procedures ,HEALTH care teams ,PATIENT aftercare - Abstract
Simple Summary: Cervical cancer, a very aggressive gynecological malignancy that also affects young women, remains significantly prevalent despite worldwide efforts in HPV vaccination campaigns. Cervical cancer research is experiencing a period of significant change, with intense ongoing debates on issues that could potentially transform current guidelines. Therefore, in light of these changes, guidelines and protocols will soon need significant updates. Hence, this paper aims to summarize and compare the most recent recommendations published by international gynecological oncology societies for patients with cervical cancer. A comparative analysis of American, Asian, and European guidelines was conducted to evaluate the different recommendations for diagnostic, surgical, medical, and follow-up management. Cervical cancer continues to have a significant incidence, despite global efforts in HPV vaccination campaigns. Managing this condition involves a diverse team of healthcare professionals. Research in this field is undergoing a period of great revolution in multiple areas, and international guidelines will soon have to adapt to new scientific evidence. This could be true mainly in locally advanced stages, and it could also be true for minimal invasive surgery. This paper aims to summarize and compare the most recent recommendations published by international gynecological oncological societies for patients with cervical cancer. From their comparison, common aspects and disagreements emerged, especially in the diagnostic pathway and follow-up strategies. Several issues that remain to be debated in the literature were addressed and compared, highlighting similarities and differences, from the role of the sentinel lymph node in early stages to that of the adjuvant hysterectomy in locally advanced tumors. On the surgical side, for this last subset of patients, currently, a laparotomic approach is recommended. At the same time, the advent of immunotherapy has just opened up new and promising scenarios in systemic treatment for locally advanced cervical cancer, and international guidelines will soon introduce it into their algorithms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Circulating microRNAs in Cancer: A 5-Year Update with a Focus on Breast and Lung Cancers.
- Author
-
Siniscalco, Dario, Galderisi, Umberto, Peluso, Gianfranco, and Finicelli, Mauro
- Subjects
LUNG cancer ,BREAST cancer ,MICRORNA ,CANCER research ,NON-coding RNA ,CIRCULAR RNA - Abstract
Circulating microRNAs (c-miRNAs) are non-coding RNAs found in different bodily fluids and are highly investigated for their prognostic potential and biological role in cancer. In this narrative review, we provide an update of the last five years' published papers (2018–2023) on PubMed about c-miRNAs in cancer research. We aim to capture the latest research interests in terms of the highly studied cancers and the insights about c-miRNAs. Our analysis revealed that more than 150 papers focusing on c-miRNAs and cancer were published in the last five years. Among these, there was a high prevalence of papers on breast cancer (BC) and lung cancer (LC), which are estimated to be the most diagnosed cancers globally. Thus, we focus on the main evidence and research trends about c-miRNAs in BC and LC. We report evidence of the effectiveness of c-miRNAs in hot topics of cancer research, such as, early detection, therapeutic resistance, recurrence risk and novel detection platform approaches. Moreover, we look at the deregulated c-miRNAs shared among BC and LC papers, focusing on miR-21 and miR-145. Overall, these data clearly indicate that the role of c-miRNAs in cancer is still a hot topic for oncologic research and that blood is the most investigated matrix. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles.
- Author
-
Yan Zhou, Min Liu, Xing Huang, Zhen Liu, Yun Sun, Minjie Wang, Tao Huang, Xianke Wang, Long Chen, and Xiaobing Jiang
- Abstract
Purpose: This study aims to depict the scientific advancements in immunotherapy for glioma by analyzing the top 100 most frequently cited articles over the past 20 years. Methods: The top 100 most influential papers in immunotherapy for glioma were identified from the Web of Science Core Collection. Citations, countries/regions, institutions, journals, authorships, keywords, and references were extracted and analyzed by CiteSpace, VOSviewer, R software, and an online bibliometric platform. Results: The United States possessed a robust global presence, leading in terms of publications and maintaining strong collaborative ties with numerous countries. The institution that made the greatest contributions was Duke University, with 16 papers. Heimberger AB, Sampson JH, and Reardon DA secured the top three positions with 15, 12, and 11 papers, respectively. “Macrophage ontogeny,” “microglia,” “polarization,” “mass cytometry,” “tumor mutation burden,” “sensitivity,” “msh6,” “pd-1 blockade,” and “dna repair” were the recent hot keywords. “Microglia” and “polarization” as the emerging research directions should be given more consideration. Conclusions: This is the first bibliometric analysis to identify the top 100 papers on immunotherapy for glioma. “Microglia” and “polarization” will be hot spots for future research. The clinical efficacy of glioma immunotherapy is not yet satisfactory, and there is an urgent need to search for more tumor specific antigens and targets that can assist in early diagnosis, precise treatment, prognosis, and recurrence prediction of glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. New era of emerging preoperative chemotherapy in gastrointestinal cancer.
- Author
-
Yamashita, Keishi
- Subjects
NEOADJUVANT chemotherapy ,GASTROINTESTINAL cancer ,CANCER chemotherapy ,RECTAL cancer ,ESOPHAGEAL cancer ,BILIARY tract cancer ,IMMUNOTHERAPY ,SURGERY - Abstract
This article discusses a JSGS paper published in the Annals of Gastroenterological Surgery. The paper focuses on the clinicopathological analysis of 460 cases of carcinoma of the ampulla of Vater (CAV) and identifies six prognostic factors. The study also explores the therapeutic strategy for CAV and suggests that preoperative chemotherapy may be the most effective treatment for aggressive CAV. The article also includes three other papers on preoperative chemotherapy in gastric cancer, colorectal cancer, and colon cancer, highlighting the potential benefits and challenges of this treatment approach. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
29. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
- Author
-
Fengqin Liu, Xia Miao, Lu Han, and Xiao Song
- Subjects
LUNG cancer ,CELLULAR therapy ,CYTOKINE release syndrome ,CANCER treatment ,CHIMERIC antigen receptors - Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide necessitating the development of innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy represents a promising advancement in the field of oncology offering a novel approach to target and eliminate tumor cells with high specificity and reduced risk of immune-related adverse effects. This paper reviews the mechanism, potential targets, and recent advances in CAR-NK cell therapy for lung cancer, including the design and engineering of CAR-NK cells, preclinical studies, and the outcomes of early-phase clinical trials. We highlight the unique advantages of using NK cells, such as their innate ability to recognize and kill cancer cells and their reduced potential for inducing graft-versus-host disease (GvHD) and cytokine release syndrome (CRS) compared to CAR T-cell therapies. Results from recent studies demonstrate significant antitumor activity in lung cancer models with improved targeting and persistence of CAR-NK cells observed in vitro and in vivo. Finally, we discuss the challenges in optimizing CAR-NK cell therapies, including the potential resistance mechanisms. The paper concludes with an outlook on the future directions of CAR-NK cell research and its implications for lung cancer treatment emphasizing the importance of continued innovation and collaboration in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Langerhans Cells in Sentinel Lymph Nodes from Melanoma Patients.
- Author
-
Gerlini, Gianni, Susini, Pietro, Sestini, Serena, Brandani, Paola, Giannotti, Vanni, and Borgognoni, Lorenzo
- Subjects
EPITHELIAL cells ,MELANOMA ,SENTINEL lymph nodes ,IMMUNOTHERAPY ,CANCER patients ,DESCRIPTIVE statistics ,SYSTEMATIC reviews ,MEDLINE ,METASTASIS ,ONLINE information services ,QUALITY assurance ,DENDRITIC cells - Abstract
Simple Summary: Melanoma, the deadliest skin cancer, is a focus of research worldwide. This malignancy has been demonstrated to evade the immune system through several escape mechanisms. Among these, melanoma-related Dendritic Cells (DCs) alterations, particularly within the Sentinel Lymph Node (SLN), seem to play a key role. In SLNs, melanoma-related factors create a tumor microenvironment capable of impairing the immune response, inducing tolerance to tumor antigens and thus favoring SLN early metastases. The present literature review describes the interactions between Langerhans Cell (LC), a particular DC subset, and melanoma, suggesting a new potential therapeutic target. Background. Langerhans cells (LCs) are professional Dendritic Cells (DCs) involved in immunoregulatory functions. At the skin level, LCs are immature. In response to tissue injuries, they migrate to regional Lymph Nodes (LNs), reaching a full maturation state. Then, they become effective antigen-presenting cells (APCs) that induce anti-cancer responses. Notably, melanoma patients present several DC alterations in the Sentinel Lymph Node (SLN), where primary antitumoral immunity is generated. LCs are the most represented DCs subset in melanoma SLNs and are expected to play a key role in the anti-melanoma response. With this paper, we aim to review the current knowledge and future perspectives regarding LCs and melanoma. Methods. A systematic review was carried out according to the PRISMA statement using the PubMed (MEDLINE) library from January 2004 to January 2024, searching for original studies discussing LC in melanoma. Results. The final synthesis included 15 articles. Several papers revealed significant LCs–melanoma interactions. Conclusions. Melanoma immune escape mechanisms include SLN LC alterations, favoring LN metastasis arrival/homing and melanoma proliferation. The SLN LCs of melanoma patients are defective but not irreversibly, and their function may be restored by appropriate stimuli. Thus, LCs represent a promising target for future immunotherapeutic strategies and cancer vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies.
- Author
-
Cech, Paweł, Skórka, Katarzyna, Dziki, Laura, and Giannopoulos, Krzysztof
- Subjects
ONCOLYTIC virotherapy ,HEMATOLOGIC malignancies ,T cells ,LYMPHOCYTIC leukemia ,ANTINEOPLASTIC agents ,IMMUNOTHERAPY ,IMMUNOGLOBULINS ,PROTEIN-tyrosine kinase inhibitors ,HEMATOLOGY ,MONOCLONAL antibodies ,CELL lines ,CANCER chemotherapy ,IMMUNE checkpoint inhibitors ,MOLECULAR structure - Abstract
Simple Summary: Recent advancements in cancer research have proven immunotherapies to be a promising strategy for the treatment of hematological malignancies. The bispecific antibody (BsAb) format was developed to overcome the issues of monoclonal antibody-based therapies. T-cell engagers (TCEs) are BsAbs, which directly activate T-cells and their anti-tumor features, ultimately resulting in the lysis of the targeted tumor cells. In 2014, the FDA approved blinatumomab for treatment of acute lymphoblastic leukemia. As of November 2023, seven clinically approved TCE therapies are on the market. In this paper, we summarized the technical basis of the TCE technology, its application in hematology, and its current issues and prospects. Recent advancements in cancer immunotherapy have made directing the cellular immune response onto cancer cells a promising strategy for the treatment of hematological malignancies. The introduction of monoclonal antibody-based (mAbs) targeted therapy has significantly improved the prognosis for hematological patients. Facing the issues of mAb-based therapies, a novel bispecific antibody (BsAb) format was developed. T-cell engagers (TCEs) are BsAbs, which simultaneously target tumor-associated antigens on tumor cells and CD3 molecules present on T-cells. This mechanism allows for the direct activation of T-cells and their anti-tumor features, ultimately resulting in the lysis of tumor cells. In 2014, the FDA approved blinatumomab, a TCE directed to CD3 and CD19 for treatment of acute lymphoblastic leukemia. Since then, numerous TCEs have been developed, allowing for treating different hematological malignancies such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma and Hodgkin lymphoma. As of November 2023, seven clinically approved TCE therapies are on the market. TCE-based therapies still have their limitations; however, improving the properties of TCEs, as well as combining TCE-based therapies with other forms of treatment, give hope to find the cures for currently terminal diseases. In this paper, we summarized the technical basis of the TCE technology, its application in hematology, and its current issues and prospects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma.
- Author
-
Vargas, Gracia Maria, Shafique, Neha, Xu, Xiaowei, and Karakousis, Giorgos
- Abstract
Tumor-infiltrating lymphocytes (TILs) have been investigated as prognostic factors in melanoma. Recent advancements in assessing the tumor microenvironment in the setting of more widespread use of immune checkpoint blockade have reignited interest in identifying predictive biomarkers. This review examines the function and significance of TILs in cutaneous melanoma, evaluating their potential as prognostic and predictive markers. A literature search was conducted on papers covering tumor infiltrating lymphocytes in cutaneous melanoma available online in PubMed and Web of Science from inception to 1 December 2023, supplemented by citation searching. This article encompasses the assessment of TILs, the role of TILs in the immune microenvironment, TILs as a prognostic factor, TILs as a predictive factor for immunotherapy response, and clinical applications of TILs in the treatment of cutaneous melanoma. Tumor-infiltrating lymphocytes play a heterogeneous role in cutaneous melanoma. While they have historically been associated with improved survival, their status as independent prognostic or predictive factors remains uncertain. Novel methods of TIL assessment, such as determination of TIL subtypes and molecular signaling, demonstrate potential for predicting therapeutic response. Further, while their clinical utility in risk-stratification in melanoma treatment shows promise, a lack of consensus data hinders standardized application. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions.
- Author
-
Rajan, Arun, Sivapiromrat, Alisa K., and McAdams, Meredith J.
- Subjects
COMBINATION drug therapy ,IMMUNOLOGICAL tolerance ,GENOMICS ,PATIENT safety ,THYMOMA ,IMMUNOTHERAPY ,CANCER patients ,TREATMENT effectiveness ,THYMUS tumors ,IMMUNE checkpoint inhibitors ,QUALITY of life ,SURVIVAL analysis (Biometry) ,QUALITY assurance ,BIOMARKERS ,EPITHELIAL cell tumors - Abstract
Simple Summary: Immune checkpoint inhibitors have revolutionized cancer therapy and improved clinical outcomes. Immunotherapy is now increasingly combined with chemotherapy and other conventional treatments, such as radiation therapy, as part of the multimodal treatment of earlier-stage cancers. Although generally well tolerated and capable of inducing long-lasting responses, immunotherapy for thymic epithelial tumors can be challenging due to defects in immune self-tolerance, which increase the risk of immune-mediated toxicity. In order to improve the safety of immunotherapy and maximize clinical benefit in patients with thymic cancers, there is a pressing need to identify potential biomarkers of response and toxicity for this patient population. In this paper, we review the current role of immunotherapy for thymic cancers and discuss future applications across the spectrum of stage and histology of these diseases. Thymic epithelial tumors are a histologically diverse group of cancers arising from the epithelial compartment of the thymus. These tumors are characterized by a low tumor mutation burden, a lack of actionable genomic changes, and, especially with thymomas, defects in immune tolerance. Surgery is the mainstay of the management of resectable disease, whereas advanced, unresectable tumors are treated with platinum-based chemotherapy. Disease recurrence can occur months to years after frontline treatment. Although several options are available for conventional treatment of recurrent thymic tumors, response rates are generally low, and treatment-related toxicity can affect quality of life. A subset of patients benefit from biologic therapies, but there remains an unmet need for the development of new treatments. Immune checkpoint inhibitors are safe, clinically active, and have contributed to an improvement in survival for patients with a wide variety of cancers. However, the application of these revolutionary treatments for thymic cancers is limited to their use for the management of recurrent thymic carcinoma because of the risk of immune toxicity. In this paper, we review the current uses of immunotherapy for the management of thymic epithelial tumors and highlight potential strategies to improve safety and broaden the application of these treatments for patients with thymic cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
- Author
-
Jaromin, Maciej, Konecki, Tomasz, and Kutwin, Piotr
- Subjects
THERAPEUTIC use of antineoplastic agents ,NON-muscle invasive bladder cancer ,CONSERVATIVE treatment ,CYSTECTOMY ,CABAZITAXEL ,CISPLATIN ,BCG vaccines ,IMMUNOTHERAPY ,CANCER patients ,TREATMENT effectiveness ,DRUG delivery systems ,DRUG approval ,MONOCLONAL antibodies ,CANCER chemotherapy ,QUALITY of life ,GEMCITABINE ,WELL-being - Abstract
Simple Summary: Bladder cancer is a common disease in urological patients. The approach to treatment depends on the severity of the tumor; in this article, we focus on tumors that do not invade the muscle layer of the bladder. Those tumors are resected during an endoscopic procedure (TURBT), but often reoccur. Treating bladder cancer with drugs instead of surgical removal of the bladder (radical cystectomy) is paramount for patients quality of life and overall well-being. The aim of this paper is to review methods of conservative treatment of tumors unresponsive to the typical treatment of choice (BCG instillations). Bladder cancer is the 10th most popular cancer in the world, and non-muscle-invasive bladder cancer (NMIBC) is diagnosed in ~80% of all cases. Treatments for NMIBC include transurethral resection of the bladder tumor (TURBT) and intravesical instillations of Bacillus Calmette-Guérin (BCG). Treatment of BCG-unresponsive tumors is scarce and usually leads to Radical Cystectomy. In this paper, we review recent advancements in conservative treatment of BCG-unresponsive tumors. The main focus of the paper is FDA-approved medications: Pembrolizumab and Nadofaragene Firadenovec (Adstiladrin). Other, less researched therapeutic possibilities are also included, namely: N-803 immunotherapy, TAR-200 and TAR-210 intravesical delivery systems and combined Cabazitaxel, Gemcitabine and Cisplatin chemotherapy. Conservative treatment and delaying radical cystectomy would greatly benefit patients' quality of life; it is undoubtedly the future of BCG-unresponsive NMIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Review of the Literature and Current State of Knowledge on the Management of Lung Neuroendocrine Neoplasms.
- Author
-
Jurkiewicz, Krzysztof, Miciak, Michał, and Kaliszewski, Krzysztof
- Subjects
NEUROENDOCRINE tumors ,POSITRON emission tomography computed tomography ,LITERATURE reviews ,KNOWLEDGE management ,ENDOCRINE cells - Abstract
Lung neuroendocrine neoplasms (LNENs) are lesions originating from diffuse endocrine cells within the bronchial walls and lung parenchyma. In recent years, there have been significant advances in the diagnosis and therapy of these neoplasms. This paper reviews recent developments in these areas, focusing on the latest research and treatment strategies. In the context of diagnosis, new imaging technologies including high-resolution computed tomography (CT), high-resolution and positron emission tomography-computed tomography (PET-CT) imaging, are providing more precise information on tumor spread and evaluation of metabolic activity. Advances in the field of molecular biomarkers allow a more personalized approach to the diagnosis of LNENs. In the therapeutic area, new targeted drugs and immunotherapy are showing promise in the treatment of LNENs. The development of molecular therapies such as tyrosine kinase inhibitors and somatostatin analogs, is opening up new treatment perspectives, increasing the efficacy of therapy, and improving patient quality of life. The paper also focuses on important research directions and clinical advances in the diagnosis and therapy of LNENs, presenting the current state of knowledge about these rare tumors. The conclusions aim to provide a synthetic view of the latest developments in the field, encouraging further research and improving treatment strategies for LNENs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Deciphering the role of CD47 in cancer immunotherapy.
- Author
-
Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P, Shi Y, Wang P, and Fang L
- Subjects
- Humans, Receptors, Immunologic metabolism, Receptors, Immunologic immunology, Animals, Signal Transduction, Antigens, Differentiation immunology, Antigens, Differentiation metabolism, Immunity, Innate, Phagocytosis, CD47 Antigen metabolism, CD47 Antigen immunology, Neoplasms therapy, Neoplasms immunology, Immunotherapy methods
- Abstract
Background: Immunotherapy has emerged as a novel strategy for cancer treatment following surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric antigen receptor (CAR)-T cell therapies have been successful in clinical trials. Cancer cells evade immune surveillance by hijacking inhibitory pathways via overexpression of checkpoint genes. The Cluster of Differentiation 47 (CD47) has emerged as a crucial checkpoint for cancer immunotherapy by working as a "don't eat me" signal and suppressing innate immune signaling. Furthermore, CD47 is highly expressed in many cancer types to protect cancer cells from phagocytosis via binding to SIRPα on phagocytes. Targeting CD47 by either interrupting the CD47-SIRPα axis or combing with other therapies has been demonstrated as an encouraging therapeutic strategy in cancer immunotherapy. Antibodies and small molecules that target CD47 have been explored in pre- and clinical trials. However, formidable challenges such as the anemia and palate aggregation cannot be avoided because of the wide presentation of CD47 on erythrocytes., Aim of View: This review summarizes the current knowledge on the regulation and function of CD47, and provides a new perspective for immunotherapy targeting CD47. It also highlights the clinical progress of targeting CD47 and discusses challenges and potential strategies., Key Scientific Concepts of Review: This review provides a comprehensive understanding of targeting CD47 in cancer immunotherapy, it also augments the concept of combination immunotherapy strategies by employing both innate and adaptive immune responses., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
37. Breakthroughs in road mapping IL-35 mediated immunotherapy for type-1 and autoimmune diabetes mellitus.
- Author
-
Chakraborty R, Mukherjee AK, and Bala A
- Subjects
- Humans, Animals, B-Lymphocytes, Regulatory immunology, Macrophages immunology, Macrophages metabolism, Diabetes Mellitus, Type 1 immunology, Diabetes Mellitus, Type 1 therapy, Immunotherapy methods, Interleukins immunology, Interleukins genetics, Interleukins metabolism
- Abstract
IL-35 is a recently discovered protein made up of IL-12α and IL-27β chains. It is encoded by IL12A and EBI3 genes. Interest in researching IL-35 has significantly increased in recent years, as evidenced by numerous scientific publications. Diabetes is on the rise globally, causing more illness and death in developing countries. The International Diabetes Federation (IDF) reports that diabetes is increasingly affecting children and teenagers, with varying rates across different regions. Therefore, scientists seek new diabetes treatments despite the growth of drug research. Recent research aims to emphasize IL-35 as a critical regulator of diabetes, especially type 1 and autoimmune diabetes. This review provides an overview of recent research on IL-35 and its link to diabetes and its associated complications. Studies suggest that IL-35 can offer protection against type-1 diabetes and autoimmune diabetes by regulating macrophage polarization, T-cell-related cytokines, and regulatory B cells (Bregs). This review will hopefully assist biomedical scientists in exploring the potential role of IL-35-mediated immunotherapy in treating diabetes. However, further research is necessary to determine the exact mechanism and plan clinical trials., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. pH/glutathione-responsive theranostic nanoprobes for chemoimmunotherapy and magnetic resonance imaging of ovarian cancer cells.
- Author
-
Wu X, Wen X, Lin X, Wang X, Wan Y, Gao R, Zhang Y, and Han C
- Subjects
- Female, Humans, Hydrogen-Ion Concentration, Indoles chemistry, Indoles pharmacology, Polymers chemistry, Animals, Cell Line, Tumor, Nanoparticles chemistry, Silicon chemistry, Particle Size, Surface Properties, B7-H1 Antigen metabolism, Drug Delivery Systems, Drug Screening Assays, Antitumor, Mice, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms therapy, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Immunotherapy methods, Glutathione chemistry, Magnetic Resonance Imaging, Theranostic Nanomedicine, Paclitaxel pharmacology, Paclitaxel chemistry, Paclitaxel administration & dosage
- Abstract
The integration of immunotherapy and standard chemotherapy holds great promise for enhanced anticancer effects. In this study, we prepared a pH- and glutathione (GSH)-sensitive manganese-doped mesoporous silicon (MMSNs) based drug delivery system by integrating paclitaxel (PTX) and anti-programmed cell death-ligand 1 antibody (aPD-L1), and encapsulating with polydopamine (PDA) for chemoimmunosynergic treatment of ovarian cancer cells. The nanosystem was degraded in response to the tumor weakly acidic and reductive microenvironment. The Mn
2+ produced by degradation can be used as a contrast agent for magnetic resonance (MR) imaging to provide visual exposure to tumor tissue. The released PTX can not only kill tumor cells directly, but also induce immunogenic death (ICD) of tumor cells, which can play a synergistic therapeutic effect with aPD-L1. Therefore, our study is expected to provide a promising strategy for improving the efficacy of cancer immunotherapy and the detection rate of cancer., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
39. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
- Author
-
Li T, Chen G, Lin L, Li B, Wang X, Chen Y, Huang W, Cai M, Xiao Z, Shuai X, and Zhu K
- Subjects
- Animals, Cell Line, Tumor, Mice, Nanoparticles chemistry, Mice, Inbred BALB C, Female, Dendritic Cells immunology, Dendritic Cells drug effects, Biomimetic Materials chemistry, Neoplasms therapy, Neoplasms immunology, Nanovaccines, Manganese Compounds chemistry, Cancer Vaccines immunology, Oxides chemistry, T-Lymphocytes immunology, T-Lymphocytes drug effects, Immunotherapy methods
- Abstract
The development of manganese oxide-based chemodynamic immunotherapy is emerging as a key strategy against solid tumors. However, the limited efficacy of nanoplatform in inducing efficient tumor therapeutic effects and creating the prominent antitumor immune responses remains a crucial issue. In this study, we construct a novel multifunctional biomimetic nanovaccine comprising manganese oxide-loaded poly(2-diisopropylaminoethyl methacrylate) (MP) nanoparticles and a coating layer of hybrid cell membrane (RHM) derived from manganese oxide-remodeled 4T1 cells and dendritic cells (DCs) (collectively called MP@RHM) for combination chemodynamic immunotherapy. Compared with the nanovaccines coated with the single cell membrane, the MP@RHM nanovaccine highly efficiently activates both DCs and T cells to boost tumor-specific T cell, owing to the synergistic effects of abundant damage-associated molecular patterns, Mn
2+ , and T cell-stimulating moieties. Upon peritumoral injection, the MP@RHM nanovaccine targets both the tumor site for focused chemodynamic therapy and the lymph nodes for robust tumor-specific T cell priming, thereby achieving highly efficient chemodynamic immunotherapy. Moreover, as a preventive cancer nanovaccine, MP@RHM generates strong immunological memory to inhibit postoperative tumor metastasis and recurrence. Our study findings highlight a promising approach to construct a multifunctional biomimetic nanovaccine for personalized chemodynamic immunotherapy against solid tumors., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
40. Hypoxia-accelerating pyroptosis nanoinducers for promoting image-guided cancer immunotherapy.
- Author
-
Liu D, Liang M, Tao Y, Liu H, Liu Q, Bing W, Li W, and Qi J
- Subjects
- Animals, Mice, Humans, Cell Line, Tumor, Mice, Inbred BALB C, Female, Neoplasms therapy, Neoplasms drug therapy, Nanoparticles chemistry, Metal-Organic Frameworks chemistry, Pyroptosis drug effects, Immunotherapy methods, Photochemotherapy methods
- Abstract
Precise image-guided cancer immunotherapy holds immense potential in revolutionizing cancer treatment. The strategies facilitating activatable imaging and controlled therapeutics are highly desired yet to be developed. Herein, we report a new pyroptosis nanoinducer that integrates aggregation-induced emission luminogen (AIEgen) and DNA methyltransferase inhibitor with hypoxia-responsive covalent organic frameworks (COFs) for advanced image-guided cancer immunotherapy. We first synthesize and compare three donor-acceptor type AIEgens featuring varying numbers of electron-withdrawing units, and find that the incorporation of two acceptors yields the longest response wavelength and most effective photodynamic therapy (PDT) property, surpassing the performance of analogs with one or three acceptor groups. A COF-based nanoplatform containing AIEgen and pyroptosis drug is successfully constructed via the one-pot method. The intra-COF energy transfer significantly quenches AIEgen, in which both fluorescence and PDT properties greatly enhance upon hypoxia-triggered COF degradation. Moreover, the photodynamic process exacerbates hypoxia, accelerating pyroptosis drug release. The nanoagent enables sensitive delineation of tumor site through in situ activatable fluorescence signature. Thanks to the exceptional ROS production capabilities and hypoxia-accelerating drug release, the nanoagent not only inhibits primary tumor growth but also impedes the progression of distant tumors in 4T1 tumor-bearing mice through potent pyroptosis-mediated immune response. This research introduces a novel strategy for achieving activatable phototheranostics and self-accelerating drug release for synergetic cancer immunotherapy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Energy-storing DNA-based hydrogel remodels tumor microenvironments for laser-free photodynamic immunotherapy.
- Author
-
Zhao H, Wang Z, Yang S, Zhang R, Guo J, and Yang D
- Subjects
- Animals, Female, Mice, Mice, Inbred BALB C, Humans, Cell Line, Tumor, Lasers, Photochemotherapy methods, Tumor Microenvironment drug effects, Hydrogels chemistry, Immunotherapy methods, Photosensitizing Agents pharmacology, Photosensitizing Agents chemistry, Photosensitizing Agents therapeutic use, DNA
- Abstract
Photodynamic therapy (PDT) is a promising modality for cancer treatment. However, limited tissue penetration of external radiation and complicated tumor microenvironments (TMEs) restrict the antitumor efficiency of PDT. Herein, we report an energy-storing DNA-based hydrogel, which enables tumor-selective PDT without external radiation and regulates TMEs to achieve boosted PDT-mediated tumor immunotherapy. The system is constructed with two ultralong single-stranded DNA chains, which programmed partial complementary sequences and repeated G-quadruplex forming AS1411 aptamer for photosensitizer loading via hydrophobic interactions and π-π stacking. Then, energy-storing persistent luminescent nanoparticles are incorporated to sensitize PDT selectively at tumor site without external irradiation, generating tumor antigen to agitate antitumor immune response. The system catalytically generates O
2 to alleviate hypoxia and releases inhibitors to reverse the IDO-related immunosuppression, synergistically remodeling the TMEs. In the mouse model of breast cancer, this hydrogel shows a remarkable tumor suppression rate of 78.3 %. Our study represents a new paradigm of photodynamic immunotherapy against cancer by combining laser-free fashion and TMEs remodeling., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
42. Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain.
- Author
-
Zuo S, Wang Z, Jiang X, Zhao Y, Wen P, Wang J, Li J, Tanaka M, Dan S, Zhang Y, and Wang Z
- Subjects
- Animals, Female, Cell Line, Tumor, Humans, Mice, RNA, Small Interfering, Polylactic Acid-Polyglycolic Acid Copolymer chemistry, Nerve Growth Factor metabolism, Mice, Inbred BALB C, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Antineoplastic Agents pharmacology, Neuralgia chemically induced, Doxorubicin pharmacology, Nanoparticles chemistry, Immunotherapy methods
- Abstract
Sympathetic nerves play a pivotal role in promoting tumor growth through crosstalk with tumor and stromal cells. Chemotherapy exacerbates the infiltration of sympathetic nerves into tumors, thereby providing a rationale for inhibiting sympathetic innervation to enhance chemotherapy. Here, we discovered that doxorubicin increases the density and activity of sympathetic nerves in breast cancer mainly by upregulating the expression of nerve growth factors (NGFs) in cancer cells. To address this, we developed a combination therapy by co-encapsulating small interfering RNA (siRNA) and doxorubicin within breast cancer-targeted poly (lactic-co-glycolic acid) (PLGA) nanoparticles, aiming to suppress NGF expression post-chemotherapy. Incorporating NGF blockade into the nanoplatform for chemotherapy effectively mitigated the chemotherapy-induced proliferation of sympathetic nerves. This not only bolstered the tumoricidal activity of chemotherapy, but also amplified its stimulatory impact on the antitumor immune response by increasing the infiltration of immunostimulatory cells into tumors while concurrently reducing the frequency of immunosuppressive cells. Consequently, the combined nanodrug approach, when coupled with anti-PD-L1 treatment, exhibited a remarkable suppression of primary and deeply metastatic tumors with minimal systematic toxicity. Importantly, the nanoplatform relieved chemotherapy-induced peripheral neuropathic pain (CIPNP) by diminishing the expression of pain mediator NGFs. In summary, this research underscores the significant potential of NGF knockdown in enhancing immunochemotherapy outcomes and presents a nanoplatform for the highly efficient and low-toxicity treatment of breast cancer., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. The secoiridoid glycoside Gentiopicroside is a USP22 inhibitor with potent antitumor immunotherapeutic activity.
- Author
-
Lu W, Chu P, Tang A, Si L, and Fang D
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Antineoplastic Agents pharmacology, Mice, Inbred BALB C, Molecular Docking Simulation, B7-H1 Antigen metabolism, B7-H1 Antigen antagonists & inhibitors, Forkhead Transcription Factors, Iridoid Glucosides pharmacology, T-Lymphocytes, Regulatory drug effects, T-Lymphocytes, Regulatory immunology, Immunotherapy methods, Ubiquitin Thiolesterase metabolism, Ubiquitin Thiolesterase antagonists & inhibitors
- Abstract
Over the past decade, immunotherapies have brought about significant changes in how we approach the treatment of various solid tumors and blood-related cancers. However, the effectiveness of checkpoint blockade therapy has been constrained to a rate of under 30 %. A significant challenge in the realm of tumor immunotherapy revolves around comprehending the mechanisms through which regulatory T (Treg) cells induce immunosuppression. We have recently discovered that USP22 (ubiquitin-specific peptidase 22) a deubiquitinating enzyme that is increased in various tumors, is an oncogene and controls Treg immune suppressive activity for tumor evasion, providing a rationale for USP22 targeting to achieve both onco- and immuno-therapeutic efficacies. Herein, we identified the traditional Chinese secoiridoid compound gentiopicroside as a USP22 inhibitor. Gentiopicroside treatment decreased the forkhead box P3 (Foxp3) expression, which subsequently reduced Treg immune suppressive activity. Treatment of cancer cells by gentiopicroside resulted in an increase in histone 2B monoubiquitination (H2Bub) in a USP22-dependent manner and a decrease in programmed cell death ligand 1 (PD-L1) expression, both of which are known as USP22-specific substrates. Docking and molecular dynamic simulation revealed that gentiopicroside stably binds to USP22 catalytic pocket, supporting that gentiopicroside is a USP22 inhibitor. Importantly, administration of gentiopicroside to mice significantly inhibited the growth of syngenetic lung adenocarcinoma. Further analysis of intratumoral immune cells revealed a dramatic increase CD8
+ T cell production of IFN-γ and granzyme B (GZMB), confirming that gentiopicroside enhances antitumor immunity. Our study revealed that gentiopicroside is a USP22-specific inhibitor with potent antitumor therapeutic potentials., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Masson SAS.)- Published
- 2024
- Full Text
- View/download PDF
44. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation.
- Author
-
Meng Y, Sun J, and Zhang G
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Neoplasms therapy, Neoplasms immunology, Gastrointestinal Microbiome immunology, Drug Resistance, Neoplasm, Animals, Fecal Microbiota Transplantation methods, Immunotherapy methods, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor immunology
- Abstract
Anti-PD-1 immunotherapy is a cancer therapy that focuses explicitly on the PD-1 receptor found on the surface of immune cells. This targeted therapeutic strategy is specifically designed to amplify the immune system's innate capacity to detect and subsequently eliminate cells that have become cancerous. Nevertheless, it should be noted that not all patients exhibit a favourable response to this particular therapeutic modality, necessitating the exploration of novel strategies to augment the effectiveness of immunotherapy. Previous studies have shown that fecal microbiota transplantation (FMT) can enhance the efficacy of anti-PD-1 immunotherapy in advanced melanoma patients. To investigate this intriguing possibility further, we turned to PubMed and conducted a comprehensive search for studies that analyzed the interplay between FMT and anti-PD-1 therapy in the context of tumor treatment. Our search criteria were centred around two key phrases: "fecal microbiota transplantation" and "anti-PD-1 therapy." The studies we uncovered all echo a similar sentiment. They pointed towards the potential of FMT to improve the effectiveness of immunotherapy. FMT may enhance the effectiveness of immunotherapy by altering the gut microbiota and boosting the patient's immunological response. Although promising, additional investigation is needed to improve the efficacy of FMT in the context of cancer therapy and attain a comprehensive understanding of the possible advantages and drawbacks associated with this therapeutic strategy., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy.
- Author
-
Nie C, Ye J, Jiang JH, and Chu X
- Subjects
- Mice, Animals, Tumor Microenvironment drug effects, Humans, Drug Delivery Systems, Mice, Inbred C57BL, Mice, Inbred BALB C, Cell Line, Tumor, Antigen-Presenting Cells immunology, Nanoparticles chemistry, Neoplasms therapy, Neoplasms drug therapy, Neoplasms immunology, Antibiotics, Antineoplastic pharmacology, Antibiotics, Antineoplastic chemistry, Antibiotics, Antineoplastic administration & dosage, Particle Size, Immunotherapy, DNA chemistry, Doxorubicin pharmacology, Doxorubicin chemistry, Doxorubicin administration & dosage
- Abstract
A major challenge in combining cancer immunotherapy is the efficient delivery of multiple types of immunological stimulators to elicit a robust anti-tumor immune response and reprogram the immunosuppressive tumor microenvironment (TME). Here, we developed a DNA nanodevice that was generated by precisely assembling three types of immunological stimulators. The doxorubicin (Dox) component induced immunogenic cell death (ICD) in tumor cells and enhanced phagocytosis of antigen-presenting cells (APCs). Exogenous double-stranded DNA (dsDNA) could act as a molecular adjuvant to activate the stimulator of interferon genes (STING) signaling in APCs by engulfing dying tumor cells. Interleukin (IL)-12 and small hairpin programmed cell death-ligand 1 (shPD-L1) transcription templates were designed to regulate TME. Additionally, for targeted drug delivery, multiple cyclo[Arg-Gly-Asp-(d-Phe)-Cys] (cRGD) peptide units on DNA origami were employed. The incorporation of disulfide bonds allowed the release of multiple modules in response to intracellular glutathione (GSH) in tumors. The nanodevice promoted the infiltration of CD8
+ and CD4+ cells into the tumor and generated a highly inflamed TME, thereby enhancing the effectiveness of cancer immunotherapy. Our research results indicate that the nanodevice we constructed can effectively inhibit tumor growth and prevent lung metastasis without obvious systemic toxicity, providing a promising strategy for cancer combination treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
46. Nanomedicine-induced programmed cell death enhances tumor immunotherapy.
- Author
-
Lu J, Tai Z, Wu J, Li L, Zhang T, Liu J, Zhu Q, and Chen Z
- Subjects
- Humans, Animals, Autophagy drug effects, Apoptosis, Ferroptosis drug effects, Nanomedicine methods, Neoplasms therapy, Neoplasms immunology, Immunotherapy methods
- Abstract
Background: There has been widespread concern about the high cancer mortality rate and the shortcomings of conventional cancer treatments. Immunotherapy is a novel oncology therapy with high efficiency and low side effects, which is a revolutionary direction for clinical oncology treatment. However, its clinical effectiveness is uneven. Based on the redefinition and reclassification of programmed cell death (PCD) (divided into necroptosis, ferroptosis, pyroptosis, and autophagy), the role of nanomedicine-induced PCD in cancer therapy has also received significant attention. Clinical and preclinical studies have begun to combine PCD with immunotherapy., Aim of Review: In this article, we present recent research in tumor immunotherapy, provide an overview of how nanomedicine-induced PCD is involved in tumor therapy, and review how nanomedicine-induced PCD can improve the limitations of immunotherapy to enhance tumor immunotherapy. The future development of nanomedicine-mediated PCD tumor therapy and tumor immunotherapy is also proposed Key scientific concepts of overview Nanomedicine-induced PCD is a prospective method of tumor immunotherapy. Nanomedicines increase tumor site penetration and targeting ability, and nanomedicine-mediated PCD activation can stimulate powerful anti-tumor immune effects, which has a good contribution to immunotherapy of tumors., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
47. Microbiota composition effect on immunotherapy outcomes in colorectal cancer patients: A systematic review.
- Author
-
Ajab SM, Zoughbor SH, Labania LA, Östlundh LM, Orsud HS, Olanda MA, Alkaabi O, Alkuwaiti SH, Alnuaimi SM, and Al Rasbi Z
- Subjects
- Humans, Treatment Outcome, Feces microbiology, Colorectal Neoplasms microbiology, Colorectal Neoplasms immunology, Colorectal Neoplasms therapy, Colorectal Neoplasms drug therapy, Gastrointestinal Microbiome drug effects, Immunotherapy methods, Immune Checkpoint Inhibitors therapeutic use
- Abstract
Background: Immune checkpoint inhibitors (ICIs) have emerged as an effective treatment for colorectal cancer (CRC). Studies indicate that the composition of gut microbiota could potentially serve as a biomarker for predicting the clinical effectiveness of immune checkpoint inhibitors., Methods: Following PRISMA guidelines, the review was conducted after registering the protocol with PROSPERO. A comprehensive literature search was carried out across five databases: PubMed, Scopus, Web of Science, Embase, and Cochrane Library. Assessment tools from the National Institutes of Health (NIH) were used to gauge the quality of the studies., Results: A total of 5,132 papers were identified, and three studies and one conference abstract published between 2017-2022 met the inclusion criteria and were summarized in a descriptive synthesis table. These four studies were in accord with the following findings, four main phyla, Firmicutes, Bacteroidata, Actinobacteria, and Verrucomicrobiota were associated with CRC patients' clinical response toward ICIs treatment. Ruminococcaceae was predominantly related to CRC patients responding to therapy, while the Micrococcaceae family was more common among the non-responders. Bacterial taxa such as Faecalibacterium and Prevotellaceae were associated with better responses to ICIs and could be predictive biomarkers. The signature of fecal microbiota with Akkermansia muciniphila and Eubacterium rectale enrichment, and Rothia mucilaginosa depletion could independently predict better response to ICIs in patients with CRC., Conclusion: The findings have brought attention to the notable differences in terms of richness and composition of microbiota between patients who responded positively to the treatment and those who did not. Bacterial species and families, such as Faecalibacterium, Bifidobacterium, Lachnospiraceae, Akkermansia sp., Ruminococcaceae, and Prevotellaceae, have consistently surfaced as potential indicators of immunotherapeutic responses. Furthermore, this review also emphasizes the need for additional comprehensive, multi-center studies with larger sample sizes to validate reported microbiota and expand our understanding of the role of gut microbiota in CRC ICIs therapy. PROSPERO ID: CRD42021277691., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Ajab et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
48. Fe 3 O 4 Nanoparticles That Modulate the Polarisation of Tumor-Associated Macrophages Synergize with Photothermal Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) to Enhance Anti-Tumor Therapy.
- Author
-
Sun H, Wang X, Guo Z, Hu Z, Yin Y, Duan S, Jia W, Lu W, and Hu J
- Subjects
- Animals, Mice, Humans, Cell Line, Tumor, Programmed Cell Death 1 Receptor antagonists & inhibitors, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors chemistry, Combined Modality Therapy, Cell Proliferation drug effects, B7-H1 Antigen antagonists & inhibitors, Apoptosis drug effects, Photothermal Therapy methods, Squamous Cell Carcinoma of Head and Neck therapy, Squamous Cell Carcinoma of Head and Neck immunology, Head and Neck Neoplasms therapy, Head and Neck Neoplasms immunology, Head and Neck Neoplasms pathology, Tumor-Associated Macrophages drug effects, Tumor-Associated Macrophages immunology, Immunotherapy methods
- Abstract
Introduction: Traditional surgical resection, radiotherapy, and chemotherapy have been the treatment options for patients with head and neck squamous cell carcinoma (HNSCC) over the past few decades. Nevertheless, the five-year survival rate for patients has remained essentially unchanged, and research into treatments has been relatively stagnant. The combined application of photothermal therapy (PTT) and immunotherapy for treating HNSCC has considerable potential., Methods: Live-dead cell staining and CCK-8 assays proved that Fe
3 O4 nanoparticles are biocompatible in vitro. In vitro, cellular experiments utilized flow cytometry and immunofluorescence staining to verify the effect of Fe3 O4 nanoparticles on the polarisation of tumor-associated macrophages. In vivo, animal experiments were conducted to assess the inhibitory effect of Fe3 O4 nanoparticles on tumor proliferation under the photothermal effect in conjunction with BMS-1. Tumour tissue sections were stained to observe the effects of apoptosis and the inhibition of tumor cell proliferation. The histological damage to animal organs was analyzed by hematoxylin and eosin (H&E) staining., Results: The stable photothermal properties of Fe3 O4 nanoparticles were validated by in vitro cellular and in vivo animal experiments. Fe3 O4 photothermal action not only directly triggered immunogenic cell death (ICD) and enhanced the immunogenicity of the tumor microenvironment but also regulated the expression of tumor-associated macrophages (TAMs), up-regulating CD86 and down-regulating CD206 to inhibit tumor growth. The PD-1/PD-L1 inhibitor promoted tumor suppression, and reduced tumor recurrence and metastasis. In vivo studies demonstrated that the photothermal action exhibited a synergistic effect when combined with immunotherapy, resulting in significant suppression of primary tumors and an extension of survival., Conclusion: In this study, we applied Fe3 O4 photothermolysis in a biomedical context, combining photothermolysis with immunotherapy, exploring a novel pathway for treating HNSCC and providing a new strategy for effectively treating HNSCC., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 Sun et al.)- Published
- 2024
- Full Text
- View/download PDF
49. Tumor targeted porphyrin-based metal-organic framework for photodynamic and checkpoint blockade immunotherapy.
- Author
-
Liu Y, Zou B, Yang K, Jiao L, Zhao H, Bai P, Tian Y, and Zhang R
- Subjects
- Animals, Humans, Mice, Photosensitizing Agents chemistry, Photosensitizing Agents pharmacology, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors chemistry, Mice, Inbred BALB C, Singlet Oxygen metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Drug Screening Assays, Antitumor, Particle Size, Neoplasms therapy, Neoplasms immunology, Neoplasms drug therapy, Neoplasms pathology, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Photochemotherapy methods, Metal-Organic Frameworks chemistry, Metal-Organic Frameworks pharmacology, Immunotherapy methods, Porphyrins chemistry, Porphyrins pharmacology, Hyaluronic Acid chemistry
- Abstract
Photodynamic therapy (PDT) has become a promising approach and non-invasive modality for cancer treatment, however the therapeutic effect of PDT is limited in tumor metastasis and local recurrence. Herein, a tumor targeted nanomedicine (designated as PCN@HA) is constructed for enhanced PDT against tumors. By modified with hyaluronic acid (HA), which could target the CD44 receptor that expressed on the cancer cells, the targeting ability of PCN@HA has been enhanced. Under light irradiation, PCN@HA can produce cytotoxic singlet oxygen (
1 O2 ) and kill cancer cells, then eliminate tumors. Furthermore, PCN@HA exhibits fluorescence (FL)/ photoacoustic (PA) effects for multimodal imaging-guided cancer treatment. And PCN@HA-mediated PDT also can induce immunogenic cell death (ICD) and stimulate adaptive immune responses by releasing of tumor antigens. By combining with anti-PD-L1 checkpoint blockade therapy, it can not only effectively suppress the growth of primary tumor, but also inhibit the metastatic tumor growth., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
50. Liver metastases across cancer types sharing tumor environment immunotolerance can impede immune response therapy and immune monitoring.
- Author
-
Gao Y, Chen S, Wang H, Wu C, An R, Li G, Yang M, Zhou Y, Zhou Y, Xie X, Yu H, and Zhang J
- Subjects
- Humans, Prognosis, Immune Tolerance, Monitoring, Immunologic methods, Gene Expression Regulation, Neoplastic, Female, Male, Gene Expression Profiling, Biomarkers, Tumor genetics, Biomarkers, Tumor immunology, Liver Neoplasms immunology, Liver Neoplasms secondary, Liver Neoplasms therapy, Immunotherapy methods, Tumor Microenvironment immunology
- Abstract
Background: Hepatic immune tolerance might contribute to the development of therapeutic resistance to immunotherapy. However, addressing this issue is challenging since the efficacy of immunotherapy in the context of liver metastasis (LM) remains poorly studied. Here, we aimed to establish an LM common immune feature (LMCIF) score to quantify the characteristics of LM immunotolerance across cancer types for assisting clinical disease management., Methods: Large-scale clinical data were collected to identify the prognosis of LM. Multi-omics datasets of metastatic cancers with LM special immune-related pathways (LMSIPs) from the Molecular Signatures Database (MSigDB)were used to obtain an LMCIF cluster. Based on differential expression genes (DEGs), a novel LMCIF score for the LMCIF cluster was constructed. In addition, multi-omics, and immunohistochemistry (IHC) data from the public and in-house cohorts were used to explore the features of LM, and LMCIF score., Results: Patients with LM had a worse prognosis and significantly lower infiltration of immune cells than patients with metastasis to other organs when analyzed with combined clinical and RNA sequencing data. After extracting the LMCIF cluster from 373 samples by utilizing 29 LMSIPs and validating them in a microarray cohort, an LMCIF score was established to confirm the role of the immunosuppressive environment as a contributor to the poor prognosis of LM across cancer types. Moreover, this LMCIF score could be used to predict the immune response of cancer patients undergoing immunotherapy. Finally, we identified that the majority of the 31 LMCIF genes exhibited a negative correlation with TME cells in LM patients, one of them, KRT19, which possessed the strongest positive correlation with LMCIF score, was confirmed to have an immunosuppressive effect through IHC analysis., Conclusions: Our results suggest that LM across cancer types share similar immunological profiles that induce immunotolerance and escape from immune monitoring. The novel LMCIF score represents a common liver metastasis immune cluster for predicting immunotherapy response, the results of which might benefit clinical disease management., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.